PD-1 Inhibitors are a game changer

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

I get upset when I read something thinking it’s true and then find out later it isn’t, especially when it’s something important regarding cancer or lymphedema.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

My diagnosis of neuroendocrine carcinoma gave me a new perspective on life.

Reduced doses of radiation were shown to be effective for some patients with indolent orbital B-cell lymphoma, researchers said.